EGFR and non-small cell lung carcinoma: Contrary to SCLC patients with rare mutations in epidermal growth factor receptor (EGFR), about 10~30% of NSCLC patients may harbor “activating mutations” in EGFR that causes constitutive activation of the EGFR pathway and provides the benefit of abnormal tumor growth [3,4].